Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NCCN 2013：乳腺癌临床实践指南（2013.V1）

2013-04-05 MedSci MedSci原创

乳腺癌指南NCCN
关注

乳腺癌临床实践指南（2013.V1）下载 NCCN+2013V1.pdf

乳腺癌临床实践指南（2013.V1）下载

NCCN+2013V1.pdf

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2016-11-22 1e18eecdm80(暂无匿称)

    值得学习，好东西。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2014-02-08 apoenzyme

    #乳腺癌临床#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2014-01-19 xsr934006975

    挺好的东西哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2013-10-16 lvliquan

    #实践指南#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2013-04-07 旅苦化文_208

    #NCCN#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2013-04-07 yanjie6253_56072842

    #临床实践#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=157537, encodeId=d66115e5374f, content=值得学习，好东西。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e591984661, createdName=1e18eecdm80(暂无匿称), createdTime=Tue Nov 22 22:33:14 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797744, encodeId=27231e977446d, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Feb 08 03:39:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6896, encodeId=9301689670, content=挺好的东西哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ea194224, createdName=xsr934006975, createdTime=Sun Jan 19 11:33:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030971, encodeId=194d20309e1a5, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Oct 16 15:39:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319674, encodeId=9ec513196e4ed, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323592, encodeId=2116132359229, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571921, encodeId=0ef515e1921cd, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sun Apr 07 13:39:00 CST 2013, time=2013-04-07, status=1, ipAttribution=)]
    2013-04-07 lily1621

    #临床实践指南#

    0

相关资讯

MOL THER ：科学家研究口服乳腺癌疫苗

　　辛辛那提大学(UC)癌症研究所和美国国立卫生研究院(NIH)进行的一项联合研究发现，一种新型口服乳腺癌疫苗可对癌细胞发起双重免疫系统攻击，有效避免乳腺癌的复发。 　　这是相关领域首次将口服特殊病毒---重组腺相关病毒(AAV)---作为癌症疫苗。首席研究员、辛辛那提大学医学院助理教授Jason Steel和同事们将相关研究成果发表在1月8日的《分子疗法》杂志上。 　　虽然其他口服型乳腺癌疫

CA Cancer J Clin：乳腺癌化疗后多出现轻度认知障碍

　　近日一项大规模荟萃分析得出结论——乳腺癌患者在化疗治疗后面临轻度认知功能障碍的风险。这项研究结果发表在最新一期的《临床肿瘤学杂志》（Journal of Clinical Oncology）。“一般而言，化疗后认知功能障碍仅为轻度且局限于言语能力方面，如措词能力，和空间视觉能力，如在陌生环境中很容易迷路，” Heather Jim博士说，他是本文首席作者，也是位于弗罗里达州的H. Lee Mo

NEJM: 乳腺癌放疗增加缺血性心脏病风险

缺血性心脏病的累积发生率 乳腺癌放疗往往涉及一些偶然的心脏对电离辐射的暴露。这种暴露对以后缺血性心脏病风险的影响尚不确定。英国牛津大学Darby博士及其同事对此进行了深入研究，他们发现在乳腺癌放疗期间心脏电离辐射暴露可导致以后缺血性心脏病的发生率增加。该病发生率的增加与心脏受照平均剂量成比例，于暴露后数年内开始，并持续至少20年。此前存在心脏风险因素的女性因放疗导致的风险绝对增加值大于其他女

上海女性缺乏维生素D 或与乳腺癌高发相关

　　记者从中科院上海生科院营养科学研究所获悉，该所王慧研究组与复旦大学附属肿瘤医院、徐汇区中心医院开展合作，对上海人群593例乳腺癌病例和580例正常对照样本的血浆中维生素D水平进行了分析，发现在未患乳腺癌女性和乳腺癌人群中，维生素D极度缺乏者（25(OH)D小于20纳克/毫升）分别占80%和99.3%。研究表明，维生素D缺乏与我国女性乳腺癌发生显著相关。在该研究人群中，25(OH)D血浆水平每增

JNCI：乳癌患者摄入高脂乳制品死亡风险大

Inez Willis, a breast cancer survivor and a senior citizen, folds her laundry in the bedroom of her independent living apartment in Silver Spring, Maryland April 11, 2012 　　近期一项针对1893名乳腺癌幸存女性进行的研究显

Clin Cancer Res：肝药酶基因变异导致他莫西芬治疗乳腺癌无效

　　乳腺癌患者某些肝药酶基因的变异使其不能很好地代谢内分泌治疗药物他莫昔芬，进而造成死亡或疾病复发的风险增高。该发现来自于一项梅奥诊所癌症中心和奥地利乳腺和结直肠癌研究组所做的研究，并发表于临床肿瘤研究杂志。 　　研究发现，和CYP2D6活性正常的患者相比，那些具有该肝药酶基因变异的患者不能很好地代谢他莫昔芬，因而导致严重的并发症。研究的第一作者Matthew Goetz博士说：“我们的研究证实

Baidu
map
Baidu
map
Baidu
map